Skip to main content
Article thumbnail
Location of Repository

TNF-alpha in asthma

By Mike A. Berry, Christopher E. Brightling, Ian D. Pavord and Andrew J. Wardlaw


This is the authors' final draft of the paper published as Current Opinion in Pharmacology, 2007, 7(3), pp. 279-82. The published version of record is available in Science Direct, via only 5-10% of patients with asthma are relatively unresponsive to treatment with inhaled corticosteroids, refractory asthma represents an important condition as these patients suffer considerable morbidity and mortality and consume a disproportionately large amount of health resource. Treatment options are limited and there is a large unmet clinical need for additional therapies. TNF-α is a proinflammatory cytokine, which has been implicated in many aspects of the airway pathology in asthma and has recently been highlighted as potentially important in refractory asthma. The development of neutralising biological agents against TNF-α has allowed the testing of its role in vivo. Preliminary studies have demonstrated an improvement in lung function, airway hyperresponsiveness, asthma quality of life and a reduction in exacerbation frequency in patients treated following anti-TNF-α therapy. We have reviewed the evidence associating TNF-α with asthma airway biology and summarise the findings of currently published clinical trials of anti-TNF-α therapy in asthma

Publisher: Elsevier
Year: 2007
DOI identifier: 10.1016/j.coph.2007.03.001
OAI identifier:

Suggested articles


  1. (1996). Activation of the TNF alpha-p55 receptor induces myocyte proliferation and modulates agonistevoked calcium transients in cultured human tracheal smooth muscle cells. doi
  2. (2006). An association between asthma and TNF-308G/A/ polymorphism:meta analysis. doi
  3. Evidence of a role of tumor necrosis factor alpha in refractory asthma. doi
  4. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses.
  5. NFkappa B and TNF-alpha: a positive autocrine loop in human lung mast cells? doi
  6. Potential implication of endothelial cells in bronchial asthma. doi
  7. (2006). The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. doi
  8. (2007). The safety and efficacy of Infliximab in moderate to severe chronic obstructive pulmonary disease. AJRCCM, doi
  9. (1995). TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation.
  10. (1993). Transforming growth factorbeta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. doi
  11. (1999). Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. doi
  12. (1990). Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. doi
  13. Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. doi
  14. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. doi
  15. Viral induction of a chronic asthma phenotype and genetic segregation from the acute response. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.